Home | About Us | Investor Relations | Products & Services | Science & Technology | People | News & Events | Contact Us News | Events

Search our site: 1 April 2003 Cyprotex PLC: Preliminary Results for 14 month period ended 31 December 2002 Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the 14 months to 31 December 2002. Highlights revenue for the 14 months to 31 December 2002 was £647,770 against £98,614 for the preceding 7 months to 31 October 2001 losses for the period were £3,357,182 against £386,752 for the preceding 7 months to 31 October 2001 expenditure reflects investments made to develop the business 12 deals signed including contracts with AstraZeneca, Astex Technology and Roche moved to a customised laboratory and office facility in the UK delivering high throughput automated screening and in silico technology Commenting on the results, John Nicholson, Chief Operating Officer of Cyprotex PLC, said: "In common with other companies providing products to the life sciences sector, Cyprotex has faced a tough and challenging environment in its first trading period as a public company. However, the Group has continued to focus on the development and effective delivery of its core technologies whilst highlighting to the market the technical and cost benefits of Cyprotex's products. The Board is encouraged by the level of interest in its products from major pharmaceutical and international biotech companies." Download Cyprotex Preliminary Results Including Financial Reports For further information, please contact: Cyprotex PLC John Nicholson, Chief Operating Officer Tel: +44 (0) 1625 505 100 j.nicholson@cyprotex.com www.cyprotex.com Media enquiries: Bankside Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140 henry.ht@bankside.com www.bankside.com

News Contact: Robert Morrisson Atwater, Chairman & CEO +44 1625 505 152 ir@cyprotex.com Request an information pack: Name: Email address:

Legal Disclaimer